

Tanvex BioPharma, Inc. 英屬開曼群島商泰福生技股份有限公司
(the "Company")

2022年股東常會開會通知書
Notice of 2022 Annual General Meeting

一、茲訂於台灣時間西元2022年6月17日上午9時30分假台北市中正區中山南路11號10樓張榮發基金會國際會議中心【受理股東報到時間：上午9：00起，報到處地點同開會地點】舉行本公司2022年股東常會。會議召集事由：(一)報告事項：1.2021年度營業報告。2.審計委員會審查2021年度決算表冊報告。3.2021年健全營運計畫執行情形報告。(二)承認事項：1.2021年度營業報告書及合併財務報告案。2.2021年度虧損撥補案。(三)討論事項：1.修訂本公司取得或處分資產處理程序案。2.修訂股東會議事規則案。3.修訂本公司章程案(本案應以特別決議通過)。4.解除董事競業禁止案。5.2022年度限制員工權利新股發行案。(四)選舉事項：本公司補選一席獨立董事案。(五)其他議案：解除新任董事競業禁止案。(六)臨時動議。

Please be informed that the Company's 2022 Annual General Meeting (The "Meeting") is scheduled to be convened at CHANG YUNG-FA FOUNDATION International Convention Center, 10F, No. 11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, Taiwan (R.O.C.), at 9:30 am, June 17, 2022. (The registration time is from 9:00 am at the same venue as the Meeting)

The Agenda of the Meeting:

1.Report Matters

- (1)The 2021 Business Report.
- (2)Audit Committee's review of the Annual Financial Audit Report of Year 2021.
- (3)For the 2021 Financial Report and the execution status of Sound Business Plan.

2.Acknowledgement Matters

- (1)To accept 2021 Business Report and Consolidated Financial Report.
 - (2)To accept proposal of 2021 loss make-up.
- 3.Proposals and Discussions:
- (1)To amend the Operational Procedures for Acquisition and Disposal of Assets of the Company.
 - (2)To amend the Rules of Procedure for Shareholders' Meeting of the Company.
 - (3)To amend the Company's Memorandum and Articles of Association. (To be approved by way of special resolution)
 - (4)Proposal for release the prohibition on Directors from participation in competitive business.
 - (5)To approve the issuance of 2022 Employees' Restricted Share Awards.

4.Election Matters:

By-election of one Independent Director of the Company.

5.Other Discussion Matters

Proposal for release the prohibition on new Independent Director from participation in competitive business.

6.Extemporary Motion

- 二、1.本次股東會董事應選人數：獨立董事1人。
This Annual General meeting shall elect one (1) Independent Director.
2.採提名制之候選人名單：【獨立董事：張俊彥】。
Names of nominated candidates: 【Independent Directors: Chang, Jang-Yang】。
3.候選人之學經歷等相關資料之查詢網址為：【http://mops.twse.com.tw】。
Please refer to http://mops.twse.com.tw for all candidates' detailed education background, experiences and related information.

三、發行西元2022年限制員工權利新股計畫案主要內容：請參閱附件一。

The 2022 Employee Restricted Stock Awards Plan (the "2022 RSA Plan"): Please see the attachment I.

四、依中華民國公開發行公司相關規定應說明其主要內容置於公開資訊觀測站，查詢網址為：【http://mops.twse.com.tw】。

Pursuant to the applicable public company rules of ROC, the Main Points of certain Discussion Items shall be placed on the website of MarketObservation Post System ("MOPS"), available at http://mops.twse.com.tw.

五、檢奉出席通知書及委託書各壹份，貴股東如決定親自出席者，請於「出席通知書」上簽名或蓋章後(無須寄回)，於開會當日攜往會場報到出席；如委託代理人出席時，請於「委託書」上簽名或蓋章，並親填受託代理人姓名及地址後，於開會五日前送達本公司服務代理人中國信託商業銀行代理部，以憑寄發出席簽到卡予受託代理人。

Please find enclosed the "Notice of Attendance" and "Proxy Statement". Please sign or apply your seal to the "Notice of Attendance" if you plan to attend the Meeting in person on the Meeting date (Do NOT return this by mail). Members/shareholders may appoint a proxy to attend the Meeting on his or her behalf by signing or applying their seal to this "Proxy Statement". Please send out such signed or sealed "Proxy Statement" to the Company's stock agency, the Transfer Agency Department of CTBC Bank, five (5) days prior to the Meeting date to allow the stock agency to deliver the "Attendance Card" to your proxy.

六、如有股東徵求委託書，本公司將於西元2022年5月17日製作徵求人徵求資料彙總表揭露於證基會網站，投資人如欲查詢，可直接鍵入(https://free.sfi.org.tw)至『委託書免費查詢系統』，輸入查詢條件即可。

If Members solicit proxies for the Annual General Meeting, the Company will compile a summary statement of proxy solicitation and disclose the content in the website of Securities & Futures Institute (SFI) on May 17th, 2022.Members can link with SFI's web address (https://free.sfi.org.tw) for relevant information.

七、本次股東會得以電子方式行使表決權，行使期間為：自西元2022年5月18日至2022年6月14日止，請逕登入臺灣集中保管結算所股份有限公司「股東會電子投票平台」【https://www.stockvote.com.tw】，依相關說明操作之。

The voting at this Meeting can be exercised by way of electronic method from May 18, 2022 to June 14, 2022. The members/shareholders can log in Electronic Voting Platform of Shareholders' Meeting established by Taiwan Depository and Clearing Corporation (https://www.stockvote.com.tw) directly and cast the vote according to the relevant explanations.

八、本次股東會委託書之統計驗證機構為中國信託商業銀行代理部。

The proxies shall be tallied and verified by the Transfer Agency Department of CTBC Bank.

九、敬請察照辦理為荷。

Please fill out the documents as described in the information contained herein.

此致 貴股東
To Shareholder

英屬開曼群島商泰福生技股份有限公司 董事會
Board of Directors of Tanvex BioPharma, Inc.



敬啟

英屬開曼群島商泰福生技股份有限公司 董事會
Board of Directors of Tanvex BioPharma, Inc.

COVID-19(新冠肺炎)疫情期間

- 1.請股東多加利用「股東e票通」(www.stockvote.com.tw)電子投票行使表決權。
- 2.股東欲出席股東會現場，請自備口罩並全程佩戴，且配合量測體溫。倘股東未佩戴口罩或經連續量測二次體溫有發燒達額溫攝氏37.5度或耳溫攝氏38度者，禁止股東進入股東會會場。
- 3.本公司如因疫情影響，而須變更股東會開會地點，屆時將另行公告。

COVID-19 Containment Announcement:

- 1.Shareholders are advised to excise the voting rights online by "Shareholders' e-voting platform" at www.stockvote.com.tw.
- 2.Shareholders would like to attend the 2022 Annual General meeting in person, please wear your own face mask in meeting room and cooperate with body temperature checking. According to the "Guidelines for COVID-19 Prevention in an Annual General Meeting", if Shareholders don't wear the face mask or have a fever over 37.5°C(forehead temperature)/38°C(ear temperature), Shareholders are not allowed into the meeting.
- 3.If the venue of 2022 Annual General meeting shall be moved to another place due to the impact of the new coronavirus pandemic, the further announcement will be posted at http://mops.twse.com.tw."

※※※※※※※※※※
※**本次股東常會**※
※**恕不發放紀念品**※
※※※※※※※※※※

※※※※※※※※※※
※**No Souvenir in this Meeting**※
※※※※※※※※※※

tanvex
BIOPHARMA, INC.
100003
台北市中正區重慶南路1段83號5樓
英屬開曼群島商泰福生技股份有限公司 服務代理人
中國信託商業銀行代理部
https://ecorp.ctbcbank.com/cts/index.jsp
客服語音專線：(02)6636-5566(股票代號：6541)
100003 5th Floor, NO. 83, Sec. 1, Chongqing S. Rd., Taipei, ROC
Tanvex BioPharma, Inc.
Transfer Agency Department of CTBC Bank Co., Ltd.
https://ecorp.ctbcbank.com/cts/index.jsp
TEL No.:+886-2-6636-5566 (Stock code:6541)

第 1 聯 (First copy)

第 3 聯：貴股東如親自出席請於此聯簽章後親至股東會會場辦理出席

Registration Page

111 出席通知書
Notice of Attendance

本股東決定親自出席本公司
西元2022年6月17日舉行之
股東常會，請 察照。

Please be informed that I/We
will attend 2022 Annual General
Meeting on June 17, 2022.

此 致
英屬開曼群島商泰福生技股份有限公司
To : Tanvex BioPharma, Inc.

股東：
戶號

Shareholder
No.

股東：
戶名

Name of
Shareholder

親自出席簽章處
Shareholder
Signature

2022 Annual General Meeting Notice

728

開會通知請速詳閱
親自出席無須寄回

(限向郵局窗口交寄)



台北郵局許可證
台北字第1333號

股東 台啟
Shareholder

本簽到卡未加蓋中國信託登記章者無效，股東請勿於此欄蓋章
This column is reserved for reception desk

中國信託蓋章處
Sealed by CTBC

英屬開曼群島商泰福生技股份有限公司2022年股東常會
2022 Annual General Meeting of Tanvex BioPharma, Inc.

111 出席簽到卡
Attendance Card

時間：西元2022年6月17日上午9時30分
Time : 9:30 am, June 17, 2022, Taiwan Time
地點：台北市中正區中山南路11號10樓張榮發基金會國際會議中心
Venue : CHANG YUNG-FA FOUNDATION International Convention Center, 10F, No. 11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City, Taiwan (R.O.C.)

股東戶號：

Shareholder No.

持有股數：

Shareholding

728 泰福-KY
Tanvex

* A 3 0 0 7 2 8 *

委託書填表須知
Proxy Statement Instruction

- 一、委託書應依公開發行公司出席股東會使用委託書規則及本公司第八次修正之章程第62至72條規定辦理。
The use of proxies is authorized in accordance with the Regulations Governing the Use of Proxies for Attendance at Shareholder Meeting of Public Companies (the "Regulations") and Articles 62 to 72 of the Company's Eighth Amended and Restated Memorandum and Articles of Association.
- 二、股東接受他人徵求委託書前，應請徵求人提供徵求委託書之書面及廣告內容資料，或參考公司彙總之徵求人書面及廣告資料，切實瞭解徵求人與擬支持被選舉人之背景資料及徵求人對股東會各項議案之意見。
Before a member/shareholder accepts the solicitation of a proxy statement, the member/shareholder must request the solicitor to provide the literature and advertisement for solicitation of proxies, or consider the literature and advertisement for solicitation of proxies compiled by the Company in order to gain a practical understanding of the background information of the solicitor and the candidate(s) for director that the solicitor intends to elect, and of the solicitor's opinion on the agenda items in the Meeting.
- 三、股東應使用本公司印發之委託書用紙，委託書與親自出席通知書均簽名或蓋章者，視為親自出席；但委託書由股東交付徵求人或受託代理人者視為委託出席。
Please use the Proxy Statement printed by the Company. In the event that the Company receives both a signed or sealed Proxy Statement AND a Notice of Attendance from a shareholder, the shareholder will be deemed to have attended the Meeting in person unless the Proxy Statement is delivered to the solicitor or proxy agent by the member/shareholder.
- 四、委託書應由委託人親自簽名或蓋章，並應由委託人親自填具徵求人或受託代理人姓名。但信託事業或股務代理機構受委託擔任徵求人，及股務代理機構受委任擔任委託書之受託代理人者，得以當場蓋章方式代替之。
The member/shareholder shall sign or affix his/her/its seal on the proxies in person and the solicitor shall fill out the name of the solicitor or proxy agent in person in the Proxy Statement; however, in a situation where a trust enterprise or stock affairs agent acts as the solicitor and a stock affairs agent is mandated to act as the proxy agent, seals affixed on the proxies in substitution shall be permitted.
- 五、徵求人或受託代理人應於委託書上簽名或蓋章，並詳填戶號、姓名或名稱、身分證字號或統一編號、住址。受託代理人如非股東，請於股東戶號欄內填寫身分證字號或統一編號；徵求人如為信託事業、股務代理機構，請於股東戶號欄內填寫統一編號。
A solicitor or proxy agent shall sign or affix the seal in the Proxy Statement and fill out his/her/its shareholder's number, name, identification number and address. A proxy agent who is not a shareholder of the Company shall fill the identification number or unified business number in the column of Shareholder's Number. If a trust enterprise or stock affairs agent acts as the solicitor, the proxy agent shall fill its unified business number in the column of Shareholder Number.
- 六、委託書應於開會五日前送達本公司股務代理人中國信託商業銀行代理部；委託書送達股務代理人後，股東欲親自出席股東會或欲以書面或電子方式行使表決權者，應於股東會開會二日前，以書面向股務代理人為撤銷委託之通知；逾期撤銷者，以委託代理人出席行使之表決權為準。
The Proxy Statement shall be delivered to the Company's stock agent, the Transfer Agency Department of CTBC Bank, at least five (5) days prior to the Meeting date. In the event any shareholder who has appointed a proxy to attend a Meeting later decides to attend the Meeting in person or exercise his voting power by way of a written ballot or through electronic transmission, he shall, at least two (2) days prior to the date of such general meeting, serve the Transfer Agency with a separate written notice revoking his previous appointment of the proxy. Votes by way of proxy shall remain valid if the relevant shareholder fails to revoke his appointment of such proxy before the prescribed time.

附件一：發行西元2022年限制員工權利新股設計畫案主要內容：
Attachment I: The 2022 Employee Restricted Stock Awards Plan (the "2022 RSA Plan"):

(一)發行總額：本次限制員工權利新股之發行總數為1,500,000股普通股，每股面額新台幣10元。
Expected total number of the Restricted Stock Awards ("RSA") issuance: 1,500,000 ordinary shares, with par value NT\$ 10 per share.

(二)發行價格：每股無償發行。
Issue price: Each RSA will be issued without consideration.

(三)發行條件：既得條件:1.指標甲：員工於公司服務年資滿1年以上，並達成各年度員工個人績效考核高於4(含)以上，可分別達成既得條件之股份比例如下：(1)獲配限制員工權利新股當年度：50% (2)獲配限制員工權利新股次年度：50%。2.指標乙：對本公司營運業務發展有重要貢獻之員工。獲配對象:A.本公司開發之生物相似藥產品取得北美或歐洲藥證有貢獻之主要人員。i.既得時點：時點I：本限制員工權利新股發行日起1年內，取得北美或歐洲任一國家主管機關核發之一張藥證；時點II：本限制員工權利新股發行日起2年內，取得北美或歐洲任一國家主管機關核發之第二張藥證。ii.既得比例：時點I可既得50%限制員工權利新股，時點II可累計既得100%限制員工權利新股。屬於本指標之限制員工權利新股發行後，若指標獲配對象於既得時點未在职時，視為未達既得條件，本公司將依法無償收回其股份並辦理註銷。B.委託開發暨製造服務相關業務有貢獻之主要人員。i.既得時點：時點I：本限制員工權利新股發行日起，委託開發暨製造服務單一專案營收達美金一千萬以上；時點II：本限制員工權利新股發行日起，委託開發暨製造服務累積營收達美金兩千萬以上。ii.既得比例：時點I可既得50%限制員工權利新股，時點II可累計既得100%限制員工權利新股。屬於本指標之限制員工權利新股發行後，若指標獲配對象於既得時點未在职時，視為未達既得條件，本公司將依法無償收回其股份並辦理註銷。C.新產品開發有功之主要人員。i.既得時點：本限制員工權利新股發行日起2年內，本公司成功轉大分子開發產品之合約生效日。ii.既得比例：事實發生日可既得100%-之限制員工權利新股。屬於本指標之限制員工權利新股發行後，若指標獲配對象於既得時點未在职時，視為未達既得條件，本公司將依法無償收回其股份並辦理註銷。
The terms and conditions of issuance: Vesting conditions: 1.Index A: if an employee who has served in the company for 1 year or more and scores 4 or higher for his/her personal annual performance review in each year, the ratios of granted shares to be vested to the employee are set forth as follows: (1) In the year when the restricted shares are granted: 50% (2) In the second year following the restricted shares are granted: 50%. 2.Index B: employees with a significant contribution to the operation and business development of the Company. Eligible employees: A.Key personnel contributing to the granting of a North American or European market authorization to a biosimilar product developed by the Company. i. Vesting milestones: Milestone I: A market authorization granted by the competent authority of any country in North America or Europe is obtained within a year from the date of issuance of the restricted shares. Milestone II: A second market authorization granted by the competent authority of any country in North America or Europe is obtained within two years from the date of issuance of the restricted shares. ii. Vesting ratio: 50% are vested upon the completion of milestone I, and 100% are vested cumulatively upon the completion of milestone II. After the restricted shares of this index are issued, an employee will be deemed to fail to fulfill the vesting conditions if not in employment at the time of a milestone, in which case the Company will duly reacquire the shares of the employee gratis and cancel the same. B. Key personnel contributing to contract development and manufacturing related business. i. Vesting milestones: Milestone I: The operating revenue of a single contract research and manufacturing project reaches USD 10 million or above from the date of issuance of the restricted shares. Milestone II: The cumulative operating revenue of contract research and manufacturing reaches USD 20 million or above from the date of issuance of the restricted shares. ii. Vesting ratio: 50% are vested upon the completion of milestone I, and 100% are vested cumulatively upon the completion of milestone II. After the restricted shares of this index are issued, an employee will be deemed to fail to fulfill the vesting conditions if not in employment at the time of a milestone, in which case the Company will duly reacquire the shares of the employee gratis and cancel the same. C. Key personnel contributing to new product development. i. Vesting milestones: the effective date of the agreement concerning the Company's successful technology transfer or license of biologics product within two years from the date of issuance of the restricted shares. ii. Vesting ratio: 100% are vested on the date of occurrence of the fact. After the restricted shares of this index are issued, an employee will be deemed to fail to fulfill the vesting conditions if not in employment at the time of a milestone, in which case the Company will duly reacquire the shares of the employee gratis and cancel the same.

(四)員工資格條件及得獲配或認購之股數：以限制員工權利新股授予日當日已到職之本公司、國內子公司及國外子公司之全職正式員工為限。實際獲配之員工及股數，將依相關法令於參酌績效表現、整體貢獻、特殊功績或其它管理上需參考之條件與公司營運需求與發展策略等因素，由董事長提案後提報董事會同意。如被授予員工亦為本公司之董事或經理人，由董事長提案經薪酬委員會覆核後提報董事會同意。
Qualifications and conditions for employees and the numbers of shares distributable or subscribable: The eligible employees are limited to the employees of the Company or of the domestic and foreign subsidiaries who serve as the full-time employees before the RSA are granted. The eligible employees who are granted restricted shares and the number of shares granted shall be determined by the Board Chairperson by taking into consideration of their performance, entire contribution, and specific merit, as well as the Company's operating needs and as required for the business development strategies, with a proposal to be submitted to the Board of Director for approval. Those shares granted to eligible employees who take positions of Directors or Officers shall be first approved by the Compensation Committee and then the Board or Directors.

(五)辦理本次限制員工權利新股之必要理由：本公司為吸引及留任本公司所需人才，並激勵員工及提升員工向心力，以期共同創造公司及股東之利益。
The reasons why it is necessary to issue the new RSAs: To attract and retain professional personnel needed by the Company, to motivate employees and enhance their centripetal force so as to jointly create the Company's and shareholders' interests.

(六)可能費用化之金額、對公司每股盈餘稀釋情形及其他對股東權益影響：概估四年可能費用化之金額為新台幣87,150,000元，每股盈餘稀釋情形約新台幣0.247元，本次預計發行股數佔公司已發行股份總數(截至西元2021年12月底為352,454,701股)比率約為0.43%。惟限制員工權利新股尚未既得前，不計入流通在外股權數，故上述提及對每股盈餘之稀釋作用將待既得時逐期反映。
The expected amount of expenses and the dilution effect on the Company's earnings per share and any other impact on shareholder's equity: (1) It is estimated that the expected amount of expenses for four years is NT\$87,150,000 over four years. (2) The dilution effect on the Company's earnings per share is approximately NT\$0.247. The total numbers to be issued under this plan is approximately 0.43% of the Company's total issued and outstanding shares (352,454,701 shares as of December 31, 2021). However, before the restricted shares of employees are vested, they will not be included in the number of outstanding shares. The diluting effect on the earnings per share mentioned above will be reflected on a period-by-period basis when it is vested.

(七)獲配新股後未達既得條件前受限制之權利：1.員工不得將該限制員工權利新股出售、轉讓、贈與他人、設定他項權利或負擔，或為其他方式之處分。2.本公司股東會之出席、提案、發言、表決及選舉等權利皆委託信託或保管機構(以孰適用者為準)代為行使之。3.員工依本辦法獲配之限制員工權利新股，於未達既得條件前該限制員工權利新股不得享有配股、股息、現金增資認股及資本公積轉增資及資本公積配發現金之權益等權利。4.本公司發行之限制員工權利新股，被授予員工屬中華民國國籍者，員工應於被授予後立即交付本公司指定之信託機構以為信託保管，且除本辦法另有規定者外，於既得條件成就前，應持續交付信託保管。未達既得條件前因持有限制員工權利新股而得之各限制配股及股息亦需一併交付信託保管。被授予員工為其他國籍者，則以委任保管銀行方式保管之。5.被授予員工未符既得條件、離職或發生繼承等情事時之處理方式：除辦法另有訂定者外，被授予之限制員工權利新股，遇有既得條件未成就者，該等若條件成就可既得之股份由本公司全數無償收回，並予以註銷。6.其他條件，請參閱限制員工權利新股發行辦法。
Limitations to Rights Prior to Vesting Conditions are Met after New Shares are vested : 1.The grantee employee shall not sell, transfer, make gift of, create other rights or encumbrances on the RSAs, or otherwise dispose of the RSAs in any other manner. 2.All the rights to attend, the proposal rights, motion rights, speech rights, voting rights and any other shareholder rights shall be exercised by the trustee or the custodian (as applicable). 3.The restrictions (including but not limited to transfer restrictions and vesting conditions) applicable to any and all unvested RSAs (and any share derived from such RSAs for whatever reason, including share dividend, retained earning capitalization, recapitalization, reserve capitalization and any cash distributed based on such RSAs for whatever reason, including cash dividend and distribution of capital reserve in the form of cash) shall equally apply to any share derived, directly or indirectly, from and cash distributed based on such unvested RSAs for whatever reason, including share dividend, retained earning capitalization, recapitalization, reserve capitalization, cash dividend and distribution of capital reserve in the form of cash, and any interests (collectively, the "Restricted Share and Cash Distribution"). For the avoidance of doubt, for the purpose of this Plan, the unvested RSAs shall include all the corresponding Restricted Share and Cash Distribution, which are subject to the same restrictions and thus unvested. 4.In the case that the grantee employee is an ROC citizen, such employee shall, immediately after the Company issues the RSAs to such employee, trust such RSAs to the trustee designated by the Company in accordance with the Company's instruction and, unless otherwise provided hereunder, shall be continuously trusted till the full satisfaction of the vesting conditions. Any and all the Restricted Share and Cash Distribution derived from the unvested RSAs shall also be put in the trust. In the case that the grantee employee is non-ROC citizen, such employee shall put the RSA with a custodian bank for custody. 5.Employee's failure to meet the vesting conditions, termination or in the event of succession: Unless otherwise provided in the Plan, RSA failing to meet the vesting conditions shall be reacquired and cancelled by the Company without compensation. 6.Other conditions of the plan please refer to the Plan.

委託書 Proxy Statement		委託人(股東) (Proxy by shareholder)	編號 No.	728 泰福-KY Tanvex		
1.茲委託 君(須由委託人親自填寫，不得以蓋章方式代替)為本股東代理人，出席本公司西元2022年6月17日舉行之股東常會，代理人並依下列授權行使股東權利： I hereby appoint (please fill out in person, affixing the seal is not acceptable) as my proxy agent, with authorization to vote and act on my behalf at the 2022 Annual General Meeting of Tanvex BioPharma, Inc. on June 17, 2022 pursuant to the scope of authorization described below: □(1)代理本股東就會議事項行使股東權利。(全權委託) I grant my proxy full authorization to vote and act on my behalf at the Meeting and act for extempory motions during the Meeting. (Authorization granted in full scope) □(2)代理本股東就下列各項填表行使本股東所委託表示之權利與意見，下列減棄未列選者，視為對各項減棄表示承認或贊成。 I grant my proxy authorization to vote and act on my behalf at the Meeting pursuant to authorized methods of exercise described below: (If neither box is ticked, it will be deemed as "vote-for".) a.2021年度營業報告書及合併財務報告案： To accept 2021 Business Report and Consolidated Financial Report. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain b.2021年度虧損撥補案： To accept proposal of 2021 loss make-up. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain c.修訂本公司「取得或處分資產處理程序」案： To amend the Operational Procedures for Acquisition and Disposal of Assets of the Company. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain d.修訂股東會議事規則案： To amend the Rules of Procedure for Shareholders' Meeting of the Company. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain e.修訂本公司章程暨本章程以特別決議通過)： To amend the Company's Memorandum and Articles of Association. (To be approved by way of special resolution) (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain f.解除董事競業禁止案： Proposal for release the prohibition on Directors from participation in competitive business. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain g.2022年度限制員工權利新股發行案： To approve the issuance of 2022 Employees' Restricted Share Awards. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain h.本公司增設一名獨立董事案： By-election of one Independent Director of the Company. i.解除新任董事競業禁止案： Proposal for release the prohibition on new Independent Director from participation in competitive business. (1)○贊成(2)○反對(3)○棄權 (1)○For (2)○Against(3)○Abstain j.臨時動議 Extempory Motion.	一、禁止交付現金或其他利益之價購委託書行為。 Offering cash or non-cash consideration in exchange for proxies is prohibited for Proxy solicitation.	股東戶號 No.	簽名或蓋章 Sign or Seal			
	二、發現違法取得及使用委託書，可檢附具體事證向集保結算所檢舉，經查證屬實者，最高給予檢舉獎金十萬元，檢舉電話：(〇二)五四七三七三三。 Please report to Taiwan Depository & Clearing Corporation ("TDCC") supplementing with specific information when discovering any suspicious illegal obtaining or use of proxies. Once verified by TDCC, the person making the report will be granted a reward up to NTD 100,000. Report phone number: +886 2 25473733	持牌證號碼 Scheduling		徵求人 Solicitor	簽名或蓋章 Sign or Seal	
	2.本股東未於前項□內勾選授權範圍或同時勾選者，視為全權委託，但股務代理機構擔任受託代理人者，不得接受全權委託，代理人應依前項(二)之授權內容行使股東權利。 If neither authorization scope box is checked in the former item, it will be deemed as "authorization granted in full scope". However, whenever a stock affairs agent is mandated to act as the proxy agent, no authorization granted in full scope shall be permitted. The proxy agent shall vote and act on behalf the Member/Shareholder pursuant to authorization methods of exercise described as item 1.(2).	戶號 No.		姓名或稱謂 Name	受託代理人 Proxy Agent	簽名或蓋章 Sign or Seal
	3.本股東代理人得於會議臨時事宜全權處理之。 The proxy agent may have the authorization to act on the Member/Shareholder's behalf for extempory motions during the Meeting. 4.請將出席證(或出席簽到卡)寄交代理人收執，如因被改期開會，本委託書仍屬有效(限此一會期)。 Please deliver the Attendance Card to the proxy agent. This Proxy will remain effective for any adjournment or postponement of the Meeting. 此致 英屬開曼群島商泰福生技股份有限公司 授權日期 年 月 日 Tanvex BioPharma, Inc. Date of Authorization:	姓名或稱謂 Name				

徵求場所及人員簽章處：
Signature by the place of solicitation and personnel: